Osaic Holdings
EDIT icon

Osaic Holdings’s Editas Medicine EDIT Stock Holding History

Osaic Holdings’s Portfolio EDIT Stock Details EDIT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$227K Buy
70,124
+18,700
+36% +$54.7K ﹤0.01% 4322
2026
Q1 		$127K Sell
51,424
-6,330
-11% -$13.4K ﹤0.01% 4503
2025
Q4 		$118K Buy
57,754
+41,788
+262% +$121K ﹤0.01% 4570
2025
Q3 		$53.5K Buy
15,966
+369
+2% +$1.03K ﹤0.01% 5267
2025
Q2 		$34.2K Buy
15,597
+2,670
+21% +$4.37K ﹤0.01% 5317
2025
Q1 		$15K Buy
12,927
+6,889
+114% +$10.1K ﹤0.01% 5554
2024
Q4 		$7.66K Sell
6,038
-1,539
-20% -$3.92K ﹤0.01% 5953
2024
Q3 		$25.8K Sell
7,577
-9,384
-55% -$40.9K ﹤0.01% 5208
2024
Q2 		$79.2K Sell
16,961
-45,681
-73% -$258K ﹤0.01% 4320
2024
Q1 		$465K Sell
62,642
-5,779
-8% -$48K ﹤0.01% 2994
2023
Q4 		$693K Buy
68,421
+1,475
+2% +$12.9K ﹤0.01% 2876
2023
Q3 		$522K Sell
66,946
-2,812
-4% -$24.1K ﹤0.01% 3207
2023
Q2 		$574K Buy
69,758
+27,877
+67% +$243K ﹤0.01% 3035
2023
Q1 		$304K Sell
41,881
-2,212
-5% -$19.7K ﹤0.01% 3545
2022
Q4 		$392K Sell
44,093
-5,779
-12% -$63.4K ﹤0.01% 3243
2022
Q3 		$612K Sell
49,872
-3,418
-6% -$53.3K ﹤0.01% 2693
2022
Q2 		$630K Buy
53,290
+1,670
+3% +$22.4K ﹤0.01% 2705
2022
Q1 		$985K Sell
51,620
-4,265
-8% -$79.3K ﹤0.01% 2593
2021
Q4 		$1.49M Buy
55,885
+2,276
+4% +$78.3K ﹤0.01% 2043
2021
Q3 		$2.2M Sell
53,609
-17,419
-25% -$954K ﹤0.01% 1619
2021
Q2 		$4.02M Buy
71,028
+14,041
+25% +$519K 0.01% 1177
2021
Q1 		$2.41M Buy
56,987
+26,517
+87% +$1.51M 0.01% 1453
2020
Q4 		$2.14M Buy
30,470
+7,626
+33% +$313K 0.01% 1386
2020
Q3 		$643K Sell
22,844
-3,143
-12% -$102K ﹤0.01% 2204
2020
Q2 		$769K Buy
25,987
+5,084
+24% +$133K ﹤0.01% 1960
2020
Q1 		$418K Buy
+20,903
New +$527K ﹤0.01% 2248

Other funds holding EDIT

TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Osaic Holdings's EDIT Position: Q2 2026 in Review

Osaic Holdings increased its Editas Medicine (EDIT) stake by 36% in Q2 2026, buying an estimated $54.7K and bringing the position to 70,124 shares worth $227K. The position accounts for ﹤0.01% of the portfolio, ranked #4322.

Osaic Holdings first reported a position in EDIT in Q1 2020 and has held it in 26 quarters since. The position peaked at $4.02M in Q2 2021. 215 funds tracked by Wall St. Rank hold EDIT as of Q2 2026.

  • Osaic Holdings held 70,124 shares of Editas Medicine worth $227K as of Q2 2026.
  • Osaic Holdings bought 18,700 Editas Medicine shares in Q2 2026, an estimated $54.7K.
  • Editas Medicine made up ﹤0.01% of Osaic Holdings's portfolio in Q2 2026, its #4322 holding.
  • Osaic Holdings first reported a position in Editas Medicine in Q1 2020 and has held it in 26 quarters since.
  • Osaic Holdings's Editas Medicine position peaked at $4.02M in Q2 2021.
  • 215 funds tracked by Wall St. Rank held Editas Medicine as of Q2 2026.

Based on Osaic Holdings's 13F filing for Q2 2026, filed 14 Aug 2026.